|
|
COURSE FACULTY
Arnold Caplan, PhD is Professor of Biology and the Director of the Skeletal Research Center. Dr. Caplan received his PhD from
The Johns Hopkins University School of Medicine, Baltimore, Maryland in 1981. He has received the Elizabeth Winston Lanier Award given by
the American Academy of Orthopaedic Surgeons as part of their 1990 Kappa Delta Awards Program, the 1999 Marshall R. Urist Award for Excellence
in Tissue Regeneration Research given by the Orthopaedic Research Society and the Genzyme Lifetime Achievement Award given by the International
Cartilage Repair Society in 2007. He has over 350 published manuscripts and 15 issued patents. He founded Osiris Therapeutics, Inc, Cell
Targeting, Inc. and also consulting company, aCa, and has pioneered cell-based therapies in Regenerative Medicine
Douglas M. Arm, PhD currently serves as Cytori Therapeutics' Sr. Vice President of Operations, Dr. Arm directs the activities
of the research, development, and manufacturing departments. Dr. Arm joined the company in February 2005 as Vice President of Development,
Regenerative Cell Technology, and has overseen the development of Cytori's Celution® System for adipose-derived regenerative cell processing.
Prior to Cytori, Dr. Arm spent more than eight years at Interpore Cross International, the last several as Director of Biologics Research.
Upon Interpore's acquisition by Biomet in 2004, his responsibilities were expanded to include strategic technology evaluation and product
development across multiple business units. Before joining Interpore in 1996, Dr. Arm completed a post-doctoral fellowship studying mesenchymal
stem cells in the Skeletal Research Center at Case Western Reserve University. He obtained his B.S. in Biomedical Engineering from the Johns
Hopkins University, and his Ph.D. in Bioengineering from the University of Washington.
Lisa N. Colleran, BSN, MBA began her career as a Registered Nurse at The New York Hospital, Cornell Medical Center. In 1983
she joined Baxter Healthcare Corp. as a clinical sales specialist and served in various roles of increased responsibility in Sales, Marketing,
Business Development and general management, with significant global experience. Lisa was appointed Vice President, Marketing for US Renal
business in 1997 and served in that role until 2001 when she advanced to Vice President/General Manager, Renal Pharmaceuticals Business.
In 2002, Lisa joined LifeCell Corporation as Vice President, Marketing and Business Development. In July 2004 Lisa was promoted/named
Senior Vice President, Commercial Operations. In her role as head of LifeCell's Commercial Operations, Lisa was responsible for building
and enhancing the company's Sales, Marketing, Customer Support and Tissue Services organizations. In August 2008, Lisa was promoted to
the position of President of LifeCell and a member of KCI's Executive Committee. She holds a BSN degree from Molloy College, New York, a
nd an MBA degree from Loyola University of Chicago.
Stanton Gerson, MD is the Asa and Patricia Shiverick Professor, Director of the Case Comprehensive Cancer Center, Director
of the Ohio Wright Center for Stem Cell and Regenerative Medicine at Case School of Medicine, Cleveland, Ohio. Dr. Gerson is co-editor of
the textbook Cancer Gene Therapy. His research interests are in stem cells and DNA repair. He developed the first therapeutic trials of
mesenchymal stem cells. He identified mutant MGMT as a drug resistance gene to select for stem cells. He is developing methoxyamine,
an inhibitor of base excision repair, for clinical use. Finally, Dr. Gerson uses transgenic mouse models to examine the role of DNA r
epair in stem cell maintenance
Robert J. Hariri, MD, PhD is Chief Executive Officer of Celgene Cellular Therapeutics, is a scientist, neurosurgeon, inventor,
and businessman who has established himself as a recognized leader in the development of new human cellular and tissue therapeutics.
As founder of LifebankUSA, Dr. Hariri served as Chairman and Chief Scientific Officer before it was acquired by now parent company Celgene
Corporation. He has made his life's work the quest to bring cells into the mainstream therapeutic market place so we can better treat
and in some cases eradicate diseases such as leukemia and other cancers, anemias, heart disease, diabetes, paralysis and neurogenerative
diseases such as Parkinson's and Alzheimer's. Dr. Hariri has held academic positions at Cornell University Medical College, Cornell
University Graduate School of Medical Sciences. He has also played a prominent medical role at Cornell University Medical College,
The New York Hospital-Cornell Medical Center and The Jamaica Hospital-Cornell Trauma Center.
Robert J. Harman, DVM, MPVM is CEO, founder of Vet-Stem. Dr. Harman has more than 15 years of experience as a chief executive
and biotechnology entrepreneur in three novel businesses, all financial successes. Dr. Harman is a veterinarian and statistician, and has
overseen the completion of more than 1,000 contract research projects in his career for the development of veterinary and human biotechnology
products. He has led the following companies: HTI Bio-Services, a contract research company; HTI Bio-Products, a biological reagent and
antibody production company; and Animal Health Ventures, a veterinary product licensing company
Robert D. Hisrich MBA, PhDis the Garvin Professor of Global Entrepreneurship and Director of the Center for Global Entrepreneurship
at Thunderbird School of Global Management. He is also president of H&B Associates, a marketing and management consulting firm he founded.
Dr. Hisrich received his MBA and PhD degrees from the University of Cincinnati and honorary doctorate degrees from Chuvash State University
(Russia) and the University of Miskolc (Hungary). He has authored or co-authored twenty-one books including: Global Entrepreneurship,
Entrepreneurship: Starting, Developing, and Managing a New Enterprise, He has written over 300 articles on entrepreneurship,
international business management and venture capital. He has instituted academic and training programs in Hungary, Russia, and China.
Silviu Itescu, MBBS (Hons), FRACP, FACP, FACR is A medically trained physician scientist, Professor Itescu has
established an outstanding international reputation in the fields of stem cell biology, autoimmune diseases, organ
transplantation, and heart failure. He has been a faculty member of Columbia University in New York and of the
University of Melbourne. His pioneering work in the use of adult stem cells for heart disease has laid the groundwork
for a potential paradigm shift in the treatment of cardiovascular disorders. Professor Itescu has consulted for various
international pharmaceutical companies, has been an adviser to biotechnology and health care investor groups, and has
served on the Board of Directors of several publicly-listed life sciences companies.
Michael H. May, PhD completed his PhD in Chemical Engineering at the University of Toronto in 1998 as an NSERC Scholar,
and was awarded the Martin Walmsley Fellowship for Technological Entrepreneurship in support of the founding of Rimon Therapeutics.
He is currently the Chief Executive Officer of the Centre for Commercialization and Regenerative Medicine (CCRM). Prior to CCRM,
Michael was the President, Chief Operating Officer and co-founder of Rimon Therapeutics Ltd., a Toronto-based regenerative medicine
company developing novel medical polymers that possess drug-like activity.
Randal Mills, PhD President, CEO and BOD member of Osiris Therapeutics, Inc. Prior to joining Osiris, Dr. Mills was an
executive officer of Regeneration Technologies, Inc. Dr. Mills served at RTI from its formation in 1998 until 2004 as Vice President
of Business Development and Vice President of Operations and R&D. Prior to RTI, Dr. Mills was a member of the founding management
team of the University of Florida Tissue Bank, Inc. the predecessor company to RTI. Dr. Mills received a bachelor's degree in microbiology
and cell science and a PhD in drug development, both from the University of Florida. Osiris Therapeutics, Inc. is a leading stem cell
therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, orthopaedic and
cardiovascular areas. Osiris has partnered with Genzyme Corporation to develop Prochymaltm worldwide.
Marc Penn, MD, PhD PhD is Director of Center for Cardiovascular Cell Therapy and the Skirball Laboratory for Cardiovascular
Cellular Therapeutics at the Cleveland Clinic. He is board certified in Cardiology. He has started three companies to translate his
research and clinical experience to diagnose and treat patients with heart disease. Dr. Penn received his Ph.D. in Biomedical Engineering
and his MD from Case Western Reserve University. He completed His Cardiology Fellowship at Cleveland Clinic. He received the AHA Irving P
age Young Investigator award in 1999 and the Innovator Of The Year award from Cleveland Clinic in 2006. Since 2008 he has been the
Senior Medical Director for Emerging Businesses at Cleveland Clinic.
Glenn Prestwich, PhD Presidential Professor of Medicinal Chemistry and Special Presidential Assistant for Faculty Entrepreneurism
at the University of Utah. B.Sc. 1970, Chemistry, California Institute of Technology; Ph.D. 1974, Organic Chemistry, Stanford University; NIH
postdoctoral fellow 1974-76, Cornell University and International Centre for Insect Physiology and Ecology in Nairobi, Kenya. Co-founder:
Echelon Biosciences, Inc.; Sentrx Surgical, Inc.; Carbylan BioSurgery, Inc.; Sentrx Animal Care, Inc.; Glycosan BioSystems; Inc.; GlycoMira,
LLC.; Clear Solutions Biomedical LLC. During his 32 years as a faculty member, he has published over 600 technical papers, patents, and book
chapters, and has trained over 125 postgraduate scientists. Semi-professional photographer, commercially rated pilot, and first tenor in the
Utah Symphony Chorus.
Brock Reeve, MBA is a graduate of Yale and the Harvard Business School, is Executive Director of the Harvard Stem Cell Institute.
In partnership with the Faculty Directors, he has overall responsibility for the operations and strategy of the institute whose mission is to
use stem cells, both as tools and as therapies, to understand and treat the root causes of leading degenerative diseases.
Bernard Siegel, JD is the founder and full-time executive director of the nonprofit Genetics Policy Institute (GPI) based in
Wellington, (Palm Beach County) Florida. He is the founder and the co-chair of the World Stem Cell Summit series of global conferences and
editor-in-chief of the World Stem Cell Report. A native of Richmond, Virginia, he received his undergraduate and law degrees from the
University of Miami. He is a member of the Florida Bar since 1975. In 2003, he traded his 30-year courtroom career to found GPI, which
leads the global "Pro-Cures Movement" and Stem Cell Action Coalition. As a recognized policy expert relating to stem cell research,
regenerative medicine and cloning, Mr. Siegel works with the world's leading stem cell researchers and advocates. He works with grassroots
activists throughout the United States, raising public awareness and educating lawmakers, the media and public on stem cells and regenerative
medicine.
David S. Smith, JD is a corporate lawyer focusing on intellectual property transactions, venture financings and regulatory matters
for life sciences companies and investors and is of Counsel with Pepper Hamilton LLP, resident in its Pittsburgh office. Mr. Smith's
intellectual property-related work includes IP transactions, regulatory issues and licensing. His corporate practice is concentrated
in the organization, financing and growth of life sciences companies. He is an authority on the legal issues surrounding the use of
human biological materials and the commercial development of tissue, cell and stem cell technologies. Mr. Smith is a founder and principal
of Teregenics, LLC, He is an officer of the Tissue Engineering and Regenerative Medicine International Society and the Pittsburgh Tissue
Engineering Initiative, Inc.. He is a past member of the board of directors of the Pennsylvania Biotechnology Association.
David W. Smith, MBA joined Lonza Bioscience in January 2002 as the Business Unit Director of the emerging Cell Therapy
business. In 2004, he was promoted to Vice President, Business Development, and in December 2005 to Vice President, Cellular Therapeutics.
In this role, David assumed responsibility for contract manufacturing, process development, contract sales, and the introduction of a new
state-of-the-art therapeutic cell production facility that provides Lonza with the capacity to manufacture billions of cells per day. Since
his arrival, the cell therapy business has grown rapidly and made considerable investments in research and development, supply chain
logistics, and cGMP manufacturing facilities. Prior to joining Lonza, Mr. Smith was Vice President, Corporate Development at Claragen,
Inc. and Business Unit Director at Invitrogen. Mr. Smith spent 14 years at The Upjohn Company in various sales and marketing roles,
including leading the launch of the Parkinson's therapeutic, Mirapex. He holds a BS in Pharmacy from Duquesne University in Pittsburgh,
PA and a MBA from Wheeling Jesuit University in Wheeling, WV.
Michael D. West, PhD is the CEO of BioTime, Inc. and its subsidiaries OncoCyte Corporation, Embryome Sciences, and ES Cell
International. The Companies are focused on developing an array of research and therapeutic products using human embryonic stem cell
technology. He has focused his academic and business career on the application of developmental biology to the age-related degenerative
disease. He was Founder of Geron Corporation, from 1990-98 as Director and VP, he initiated and managed programs in telomerase
diagnostics, oligonucleotide-based telomerase inhibition as anti-tumor therapy, and the cloning and use of telomerase in
telomerase-mediated therapy wherein telomerase is utilized to immortalize human cells. 1995-98 he organized and managed the research
collaboration between Geron and its academic collaborators that led to the first isolation of human embryonic stem and human embryonic
germ cells.
Stuart K. Williams, PhD is the Chief Scientific Officer for Tissue Genesis, Inc. and the Executive and Scientific Director of the
Cardiovascular Innovation Institute, a partnership between the University of Louisville and Jewish Hospital & St. Mary's Health Care,
and a professor in the Department of Surgery. An internationally-known expert in biomedical engineering, he was recruited to the CII
and the University of Louisville in July 2007. His research spans the fields of cardiovascular bioengineering, biomaterials and diabetes
and is funded by the NIH, the United States Army, Juvenile Diabetes Research Foundation and several private corporations. He is the co-founder of
three biosciences companies and serves as a scientific advisor for several others. Williams holds 16 U.S. patents and has several additional patents
pending. He earned a B.A. in biological sciences, an M.S. in biochemistry and a PhD in cell biology at the University of Delaware. He completed a
postdoctoral fellowship in pathology at Yale University School of Medicine.
Robin R. Young, CFA is founder and president of RRY Publications and Robin Young Consulting Group, a firm specializing
in evaluating and promoting orthopaedic technologies and companies. Mr. Young is an internationally recognized expert in his field,
with over two decades of experience. Over the course of his career, he has been an active and integral part of the development,
analysis and funding of several major orthopaedic technologies including; spine cages, engineered allograft, living cell biomaterials,
anti-adhesives, third generation hemostats, calcium-based bone void products, nucleus replacement implants and dynamic stabilization
implants. After a successful career as one of the leading medical technology analysts on Wall Street, he was instrumental in forming
and managing the HealthpointCapital research and private equity practice. In concert with Healthpoint Capital, Mr. Young wrote three
highly acclaimed orthopaedic industry reference books.
|
